https://peptidepolicywatch.com/2026/10/31/why-most-drugs-in-human-trials-never-get-approved/Peptide Policy Watchen2026-10-31Why most drugs that enter human trials never get approved, and what that means for peptides https://peptidepolicywatch.com/2026/10/30/why-doctors-cant-prescribe-or-get-peptides-covered/Peptide Policy Watchen2026-10-30Why doctors can't simply prescribe most peptides, or get insurance to pay for them https://peptidepolicywatch.com/2026/10/30/questions-to-ask-your-clinician-about-peptides/Peptide Policy Watchen2026-10-30Questions to ask a clinician about peptides: a checklist for your next appointment https://peptidepolicywatch.com/2026/10/30/next-fda-compounding-advisory-meeting-ll-37-ghk-cu-dihexa/Peptide Policy Watchen2026-10-30FDA's next peptide compounding meeting: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF https://peptidepolicywatch.com/2026/10/30/hhs-six-peptides-reasons-checked-against-research/Peptide Policy Watchen2026-10-30HHS's reasons for each of the six peptides, checked against the research https://peptidepolicywatch.com/2026/10/30/hhs-peptide-policy-federal-register-comment-period/Peptide Policy Watchen2026-10-30HHS's peptide policy is in the Federal Register: what the comment period does and doesn't decide https://peptidepolicywatch.com/2026/10/30/503a-bulks-list-how-substances-get-on-it/Peptide Policy Watchen2026-10-30How a substance gets onto FDA's 503A bulks list, and why it still holds only six